Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biotech IPO Window Closed In November As Returns And Prices Plunged

This article was originally published in Scrip

Executive Summary

Did the window for US initial public offerings by biotechnology companies suddenly slammed shut in late November? Now that everyone's back at work after the Thanksgiving holiday, that appears to be the case, and it doesn't look like the biotech IPO window will reopen anytime soon.


Related Content

Voyager Cheers End Of Sanofi Partnership In Parkinson's; Investors Less Confident
BIO Notebook, Day 3: Lilly Expands R&D Site, Sigilon Raises Cash And CytomX Talks Deal Strategy
VC Roundup: October Brings Several New Venture Funds, Including Third Rock’s Fourth
Viventia's Cancer Ambitions Go To Eleven
Wave Keeps Neuro Focus Via Pfizer Collaboration For Five Metabolic Targets





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts